$ News

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Warning: CYTH is at high risk of performing badly

Lumen Technologies Appoints Former Microsoft CMO to Board

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics presents data from study, substudy of Trappsol Cyclo

This Hershey Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Cyclo Therapeutics just downgraded at Maxim, here's why

Cyclo Therapeutics just downgraded at H.C. Wainwright, here's why

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Rafael Holdings, Cyclo Therapeutics enter merger agreement

Cyclo Therapeutics falls after merger agreement with Rafael Holdings

Cyclo Therapeutics Second Quarter 2024 Earnings: Misses Expectations

Optimistic Buy Rating for Cyclo Therapeutics Amidst Promising Clinical Trials and Financial Prospects

Cyclo Therapeutics: A Buy Rating with Significant Upside Potential Based on Clinical Progress and Financial Projections

Cyclo Therapeutics reports Q2 results

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics reports Q2 net loss approximately $6M

CYTH Stock Earnings: Cyclo Therapeutics Misses EPS, Misses Revenue for Q2 2024